370
Participants
Start Date
December 17, 2020
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2026
Pembrolizumab
Administered via IV infusion at a dose of 200 mg Q3W or 400 mg Q6W
MK-4830
Administered via IV infusion at a dose of 800 mg Q3W
Belzutifan
Administered via oral tablet at a dose of 120 mg QD
Lenvatinib
Administered via oral capsule at a dose of 20 mg QD
Pembrolizumab/Quavonlimab
Administered via IV infusion at a dose of 400 mg/25 mg Q6W
Favezelimab/Pembrolizumab
Administered via IV infusion at a dose of 800 mg/200 mg Q3W
Auckland City Hospital ( Site 3700), Auckland
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 4301), Budapest
Blacktown Hospital ( Site 3601), Blacktown
St George Hospital ( Site 3602), Kogarah
Austin Health ( Site 3600), Melbourne
Royal Brisbane and Women's Hospital ( Site 3603), Herston
Laura and Isaac Perlmutter Cancer Center ( Site 3016), New York
Memorial Sloan Kettering Cancer Center ( Site 3002), New York
UPMC Cancer Center/Hillman Cancer Center ( Site 3017), Pittsburgh
Duke Cancer Institute ( Site 3015), Durham
Hospital Universitario Ramon y Cajal ( Site 3301), Madrid
Institut Claudius Regaud ( Site 3200), Toulouse
Vanderbilt University Medical Center ( Site 3004), Nashville
Henry Ford Health System ( Site 3014), Detroit
University of Iowa ( Site 3012), Iowa City
Sheba Medical Center - Oncology Division ( Site 3501), Ramat Gan
Institut De Cancerologie De Lorraine ( Site 3204), Vandœuvre-lès-Nancy
University of Chicago ( Site 3013), Chicago
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 3203), Strasbourg
UTSW Medical Center ( Site 3003), Dallas
University of California at San Francisco ( Site 3008), San Francisco
Gustave Roussy ( Site 3202), Villejuif
ONCOCENTRO APYS-ACEREY ( Site 4103), Viña del Mar
Rambam Health Care Campus-Oncology Division ( Site 3500), Haifa
James Lind Centro de Investigacion del Cancer ( Site 4108), Temuco
CIDO SpA-Oncology ( Site 4106), Temuco
Rabin Medical Center ( Site 3502), Petah Tikva
Sourasky Medical Center ( Site 3503), Tel Aviv
FALP-UIDO ( Site 4100), Santiago
Bradfordhill-Clinical Area ( Site 4101), Santiago
Hadassah Medical Center-Oncology ( Site 3504), Jerusalem
Yale-New Haven Hospital-Yale Cancer Center ( Site 3011), New Haven
Princess Margaret Cancer Centre ( Site 3101), Toronto
Jewish General Hospital ( Site 3100), Montreal
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 4402), Amsterdam
Erasmus Medisch Centrum ( Site 4401), Rotterdam
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 4201), Bydgoszcz
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4200), Warsaw
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 4202), Gdansk
Asan Medical Center ( Site 3800), Songpagu
Severance Hospital ( Site 3802), Seoul
Samsung Medical Center ( Site 3801), Seoul
Hospital Universitari Vall d Hebron ( Site 3300), Barcelona
Southampton General Hospital ( Site 3403), Southampton
The Beatson West of Scotland Cancer Centre ( Site 3405), Glasgow
Royal Preston Hospital ( Site 3406), Preston
Leicester Royal Infirmary ( Site 3408), Leicester
Barts Health NHS Trust ( Site 3401), London
Western General Hospital ( Site 3402), Edinburgh
Velindre Cancer Centre Hospital ( Site 3407), Cardiff
The Christie NHS Foundation Trust ( Site 3400), Manchester
Merck Sharp & Dohme LLC
INDUSTRY